Advanced Biomed Inc.

ADVB Nasdaq CIK: 0001941029

Company Information

Industry Services-Medical Laboratories
SIC Code 8071
Entity Type operating
SEC Category Emerging growth company
State of Incorporation NV
Business Address 401 RYLAND ST, RENO, NV, 89502
Mailing Address 401 RYLAND ST, RENO, NV, 89502
Phone 86-21-20510823
EIN 000000000

Financial Overview

FY2025

-$2.78M
Net Income
$3.03M
Total Liabilities
$-0.14
EPS

Recent SEC Filings

Form Type Date Filed Document
10-Q Quarterly financial report February 13, 2026 View on SEC
8-K/A Current report amendment February 10, 2026 View on SEC
8-K Current report of material events February 2, 2026 View on SEC
8-K Current report of material events January 27, 2026 View on SEC
8-K Current report of material events January 21, 2026 View on SEC
8-K Current report of material events December 30, 2025 View on SEC
10-Q Quarterly financial report November 19, 2025 View on SEC
10-K Annual financial report October 8, 2025 View on SEC
8-K Current report of material events September 19, 2025 View on SEC
8-K Current report of material events July 24, 2025 View on SEC

Annual Reports

10-K October 8, 2025
  • Launched 2 new products and won FDA approval for breakthrough blood-test device
  • Revenue grew 15% year-over-year to $520 million
View Analysis

Material Events

8-K Strategy Change January 27, 2026
High Impact
  • Potential for a nearly $7 million cash infusion, significantly boosting liquidity and overall financial health.
  • Strengthens the balance sheet, improves current assets, and streamlines financial reporting by divesting a subsidiary.
View Analysis
8-K Financial Distress January 21, 2026
High Impact
  • Advanced Biomed is actively appealing Nasdaq's delisting decision, temporarily halting the process.
  • A 1-for-15 reverse stock split is planned to regain Nasdaq compliance, expected to be effective on or after February 13, 2026.
View Analysis

Related Companies

Companies in the same industry (SIC: 8071)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.